NSAID Safety Review: FDA Panel Seeks Continued PRECISION From Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer’s long-term safety outcome study comparing Celebrex, ibuprofen and naproxen has its flaws, but FDA advisory committee says its data will be far superior to meta-analyses or observational studies.